Your browser doesn't support javascript.
Low anti-SARS-CoV-2 S antibody levels predict increased mortality and dissemination of viral components in the blood of critical COVID-19 patients.
Martin-Vicente, María; Almansa, Raquel; Martínez, Isidoro; Tedim, Ana P; Bustamante, Elena; Tamayo, Luis; Aldecoa, César; Gómez, José Manuel; Renedo, Gloria; Berezo, Jose Ángel; Cedeño, Jamil Antonio; Mamolar, Nuria; García Olivares, Pablo; Herrán-Monge, Rubén; Cicuendez, Ramón; Enríquez, Pedro; Ortega, Alicia; Jorge, Noelia; Doncel, Cristina; de la Fuente, Amanda; Bustamante-Munguira, Juan; Muñoz-Gómez, María José; González-Rivera, Milagros; Puertas, Carolina; Más, Vicente; Vázquez, Mónica; Pérez-García, Felipe; Rico-Feijoo, Jesús; Martín, Silvia; Motos, Anna; Fernandez-Barat, Laia; Eiros, Jose María; Dominguez-Gil, Marta; Ferrer, Ricard; Barbé, Ferrán; Trapiello, Wysali; Kelvin, David J; Bermejo-Martin, Jesús F; Resino, Salvador; Torres, Antoni.
  • Martin-Vicente M; Unidad de Infección Viral e Inmunidad, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Spain.
  • Almansa R; Group for Biomedical Research in Sepsis (BioSepsis), Instituto de Investigación Biomédica de Salamanca, (IBSAL), Gerencia Regional de Salud, Salamanca, Spain.
  • Martínez I; Hospital Universitario Río Hortega, Gerencia Regional de Salud, Valladolid, Spain.
  • Tedim AP; Centro de Investigación Biomédica en Red en Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain.
  • Bustamante E; Unidad de Infección Viral e Inmunidad, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Spain.
  • Tamayo L; Group for Biomedical Research in Sepsis (BioSepsis), Instituto de Investigación Biomédica de Salamanca, (IBSAL), Gerencia Regional de Salud, Salamanca, Spain.
  • Aldecoa C; Hospital Universitario Río Hortega, Gerencia Regional de Salud, Valladolid, Spain.
  • Gómez JM; Group for Biomedical Research in Sepsis (BioSepsis), Instituto de Investigación Biomédica de Salamanca, (IBSAL), Gerencia Regional de Salud, Salamanca, Spain.
  • Renedo G; Intensive Care Unit, Hospital Clínico Universitario de Valladolid, Gerencia Regional de Salud, Valladolid, Spain.
  • Berezo JÁ; Group for Biomedical Research in Sepsis (BioSepsis), Instituto de Investigación Biomédica de Salamanca, (IBSAL), Gerencia Regional de Salud, Salamanca, Spain.
  • Cedeño JA; Intensive Care Unit, Hospital Universitario Rio Hortega, Gerencia Regional de Salud, Valladolid, Spain.
  • Mamolar N; Group for Biomedical Research in Sepsis (BioSepsis), Instituto de Investigación Biomédica de Salamanca, (IBSAL), Gerencia Regional de Salud, Salamanca, Spain.
  • García Olivares P; Department of Anesthesiology, Facultad de Medicina de Valladolid, Valladolid, Spain.
  • Herrán-Monge R; Anesthesiology and Reanimation Service, Hospital Universitario Rio Hortega, Gerencia Regional de Salud, Valladolid, Spain.
  • Cicuendez R; Intensive Care Unit. Hospital General Universitario Gregorio Marañón, Calle del Dr. Esquerdo, Madrid, Spain.
  • Enríquez P; Intensive Care Unit, Hospital Clínico Universitario de Valladolid, Gerencia Regional de Salud, Valladolid, Spain.
  • Ortega A; Group for Biomedical Research in Sepsis (BioSepsis), Instituto de Investigación Biomédica de Salamanca, (IBSAL), Gerencia Regional de Salud, Salamanca, Spain.
  • Jorge N; Intensive Care Unit, Hospital Universitario Rio Hortega, Gerencia Regional de Salud, Valladolid, Spain.
  • Doncel C; Intensive Care Unit. Hospital General Universitario Gregorio Marañón, Calle del Dr. Esquerdo, Madrid, Spain.
  • de la Fuente A; Intensive Care Unit, Hospital Clínico Universitario de Valladolid, Gerencia Regional de Salud, Valladolid, Spain.
  • Bustamante-Munguira J; Intensive Care Unit. Hospital General Universitario Gregorio Marañón, Calle del Dr. Esquerdo, Madrid, Spain.
  • Muñoz-Gómez MJ; Group for Biomedical Research in Sepsis (BioSepsis), Instituto de Investigación Biomédica de Salamanca, (IBSAL), Gerencia Regional de Salud, Salamanca, Spain.
  • González-Rivera M; Intensive Care Unit, Hospital Universitario Rio Hortega, Gerencia Regional de Salud, Valladolid, Spain.
  • Puertas C; Intensive Care Unit, Hospital Clínico Universitario de Valladolid, Gerencia Regional de Salud, Valladolid, Spain.
  • Más V; Group for Biomedical Research in Sepsis (BioSepsis), Instituto de Investigación Biomédica de Salamanca, (IBSAL), Gerencia Regional de Salud, Salamanca, Spain.
  • Vázquez M; Intensive Care Unit, Hospital Universitario Rio Hortega, Gerencia Regional de Salud, Valladolid, Spain.
  • Pérez-García F; Group for Biomedical Research in Sepsis (BioSepsis), Instituto de Investigación Biomédica de Salamanca, (IBSAL), Gerencia Regional de Salud, Salamanca, Spain.
  • Rico-Feijoo J; Hospital Universitario Río Hortega, Gerencia Regional de Salud, Valladolid, Spain.
  • Martín S; Group for Biomedical Research in Sepsis (BioSepsis), Instituto de Investigación Biomédica de Salamanca, (IBSAL), Gerencia Regional de Salud, Salamanca, Spain.
  • Motos A; Hospital Universitario Río Hortega, Gerencia Regional de Salud, Valladolid, Spain.
  • Fernandez-Barat L; Centro de Investigación Biomédica en Red en Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain.
  • Eiros JM; Group for Biomedical Research in Sepsis (BioSepsis), Instituto de Investigación Biomédica de Salamanca, (IBSAL), Gerencia Regional de Salud, Salamanca, Spain.
  • Dominguez-Gil M; Hospital Universitario Río Hortega, Gerencia Regional de Salud, Valladolid, Spain.
  • Ferrer R; Centro de Investigación Biomédica en Red en Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain.
  • Barbé F; Group for Biomedical Research in Sepsis (BioSepsis), Instituto de Investigación Biomédica de Salamanca, (IBSAL), Gerencia Regional de Salud, Salamanca, Spain.
  • Trapiello W; Hospital Universitario Río Hortega, Gerencia Regional de Salud, Valladolid, Spain.
  • Kelvin DJ; Department of Cardiovascular Surgery, Hospital Clínico Universitario de Valladolid, Gerencia Regional de Salud, Valladolid, Spain.
  • Bermejo-Martin JF; Unidad de Infección Viral e Inmunidad, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Spain.
  • Resino S; Department of Laboratory Medicine, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
  • Torres A; Department of Laboratory Medicine, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
J Intern Med ; 291(2): 232-240, 2022 02.
Article in English | MEDLINE | ID: covidwho-1455598
ABSTRACT

BACKGROUND:

Anti-SARS-CoV-2 S antibodies prevent viral replication. Critically ill COVID-19 patients show viral material in plasma, associated with a dysregulated host response. If these antibodies influence survival and viral dissemination in ICU-COVID patients is unknown. PATIENTS/

METHODS:

We studied the impact of anti-SARS-CoV-2 S antibodies levels on survival, viral RNA-load in plasma, and N-antigenaemia in 92 COVID-19 patients over ICU admission.

RESULTS:

Frequency of N-antigenaemia was >2.5-fold higher in absence of antibodies. Antibodies correlated inversely with viral RNA-load in plasma, representing a protective factor against mortality (adjusted HR [CI 95%], p) (S IgM [AUC ≥ 60] 0.44 [0.22; 0.88], 0.020); (S IgG [AUC ≥ 237] 0.31 [0.16; 0.61], <0.001). Viral RNA-load in plasma and N-antigenaemia predicted increased mortality (N1-viral load [≥2.156 copies/ml] 2.25 [1.16; 4.36], 0.016); (N-antigenaemia 2.45 [1.27; 4.69], 0.007).

CONCLUSIONS:

Low anti-SARS-CoV-2 S antibody levels predict mortality in critical COVID-19. Our findings support that these antibodies contribute to prevent systemic dissemination of SARS-CoV-2.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Antibodies, Viral / Antigens, Viral Type of study: Prognostic study / Risk factors Limits: Humans Language: English Journal: J Intern Med Journal subject: Internal Medicine Year: 2022 Document Type: Article Affiliation country: Joim.13386

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Antibodies, Viral / Antigens, Viral Type of study: Prognostic study / Risk factors Limits: Humans Language: English Journal: J Intern Med Journal subject: Internal Medicine Year: 2022 Document Type: Article Affiliation country: Joim.13386